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Abstract 
Background: The initiation of hepatitis B virus (HBV) replication involves the formation of covalently closed circular 
DNA (cccDNA) and its transcription into pregenomic RNA (pgRNA) in hepatocyte nuclei. The regulatory mechanism of 
HBV replication by acetyltransferase is thus far not well understood, but human acetyltransferase has been reported 
as being involved in the regulation of HBV replication.
Results: Depletion of KAT8 or HAT1 via RNA interference (RNAi) markedly down-regulated HBV-DNA and pgRNA 
levels in HepG2.2.15 cells, with KAT8 knockdown reducing both HBsAg and HBeAg more than HAT1 knockdown. Con-
sistent with these observations, HBV replication regulators hepatocyte nuclear factor-4-α (HNF4α) and peroxisome 
proliferator-activated receptor gamma coactivator- (PPARGC-) 1-α were decreased following knockdown of HAT1 or 
KAT8.
Conclusions: These data suggest that KAT8 or HAT1 regulate HBV replication and may be potential drug targets of 
anti-HBV therapy.
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Background
Chronic hepatitis B virus (HBV) infection is a major 
global health issue, with over 350 million infected 
patients, who are subsequently susceptible to develop-
ment of cirrhosis and hepatocellular carcinoma (HCC) 
worldwide [1, 2]. HBV is a noncytopathic virus with a 
3.2-kb, partially double-stranded, relaxed circular (RC) 
DNA genome [3]. Following HBV infection, RC DNA 
translocates into nucleus, where it is repaired by cellu-
lar polymerase to form covalently closed circular DNA 
(cccDNA) that is subsequently transcribed into pre-core 
RNA, pgRNA, surface mRNA and X mRNA [4]. Viral 
RNAs are then transported to cytoplasm for translation 
into viral proteins (e.g., core proteins that are assembled 
to capsids). The newly synthesized viral genome can 
either be enveloped into mature viral capsids for secre-
tion or re-enter the nucleus to replenish the cccDNA 
pool [3]. Residual HBV DNA reappears in serum and 
viral capsids later [5] but can be cleared to undetectable 
levels following treatment. In light of this, chronic HBV 
infection is thus largely attributed to persistence and rep-
lication of HBV cccDNA.
Nuclear HBV cccDNA is organized into a mini-chro-
mosome by both histone and nonhistone proteins and is 
regulated in a manner similar to cellular chromatin [6]. 
A modification of chromatin architecture is required to 
allow access of condensed genomic DNA by the regu-
latory transcription machinery protein. Covalent his-
tone modifications can be performed by enzymes such 
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as histone acetyltransferases (HATs) [7]. Furthermore, 
multiple studies have observed that inhibition of histone 
deacetylase (HDAC), trichostatin A (TSA), valproic acid 
(VPA) and nicotinamide (NAM) enhances HBV replica-
tion, suggesting that histone acetylation may promote 
HBV replication [7, 8]. Taken together, this suggests that 
epigenetic regulation of cccDNA mini-chromosome is 
implicated in the early events of HBV replication [6, 7].
To investigate the acetyltransferases implicated in HBV 
replication, RNA interference screening was performed 
using a lentiviral shRNA library. By comparing the levels 
of hepatitis B surface antigen (HBsAg) and pgRNA, deple-
tion of histone acetyltransferase 1 (HAT1) or lysine acetyl-
transferase 8 (KAT8) markedly repressed HBV replication. 
In particular, knockdown of KAT8 by lentivirus-mediated 
shRNA resulted in decreased HBsAg and hepatitis B enve-
lope antigen (HBeAg) levels. In addition to this, knockdown 
of HAT1 or KAT8 down-regulated the expression of hepat-
ocyte nuclear factor-4-α (HNF4A) and peroxisome prolif-
erator-activated receptor gamma coactivator- (PPARGC-) 
1-α at the transcriptional level. These observations suggest 
that both HAT1 and KAT8 may regulate HBV replication.
Results
RNAi screening reveals acetyltransferases regulate HBV 
replication
HepG2.2.15, a stable cell line in which complete HBV-
DNA is integrated into the cell genome, can constitutively 
express HBV genes and release HBV capsids, as reflected 
by the high levels of HBsAg and HBeAg detected in con-
ditioned culture supernatant [9]. In light of these charac-
teristics, HepG2.2.15 is thus an ideal cell model to study 
HBV replication. As HBsAg is an abundant viral surface 
antigen of HBV and can be detected at an appropriate 
sensitivity in the sera of HBV carriers [10], HBsAg was 
used as the marker for the primary RNAi screen. KAT5 
shRNA lentivirus served as a positive control, as it has 
been reported that KAT5 binds to HBV cccDNA and reg-
ulates HBV replication [7], whereas the lentiviral vector 
served as a negative control.
The HBsAg level in cell supernatant was measured by 
ELISA, and cell viability was analyzed by cell prolifera-
tion assay at 96 h after lentiviral infection. Via subsequent 
analysis of the ratio of HBsAg to the number of cells, RNAi 
depletions of ATF2, HAT1, CSRP2BP, and KAT8 decreased 
the level of HBV in the supernatant, with a similar pat-
tern was observed in KAT5 (Fig. 1b). To further verify the 
roles of these target genes in HBV replication, we inves-
tigated the relative pgRNA level after their knockdown, 
using qRT-PCR, as pgRNA not only serves the template of 
HBV RC DNA but also encodes viral replication proteins 
(i.e., the polymerase (P) and core protein (C)) [11, 12]. 
We observed RNAi depletion of HAT1 or KAT8 resulted 
in a markedly decrease by ~40 and ~60 % in the level of 
pgRNA, which is consistent with the level observed in 
KAT5 [7], whereas ATF2 knockdown did not show this 
trend (Fig. 1c). Taken together, HAT1 and KAT8 are sug-
gested to be involved in the regulation of HBV replication.
HAT1 and KAT8 regulate HBV replication by suppressing 
the expression of HBsAg, HBeAg and HBV‑DNA
The modulatory role of each shRNAs for both HAT1 and 
KAT8 in HBV replication was determined using a lentivi-
ral vector as a carrier (Fig.  2a). HAT1 shRNA1 inhibited 
HBV replication by 0.64 (SD: 0.02) folds. HAT1 shRNA2 
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Fig. 1 RNAi screening reveals acetyltransferases regulate HBV 
replication. a Flowchart of RNAi screening. b The relative HBsAg after 
screen. HepG2.2.15 cells were infected with lentiviral shRNA library. 
HBsAg was measured by ELISA and cell growth was determined by 
MTS assay at 96 h after infection. The relative HBV level is given by the 
ratio of HBsAg/MTS. c Relative levels of pgRNA after screen. pgRNA 
was measured by qRT-PCR at 72 h after infection. The lentiviral vector 
served as a negative control and, KAT5 shRNA lentivirus served as a 
positive control, as it was reported that KAT5 bound to HBV cccDNA 
and regulate HBV replication
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Fig. 2 The most inhibitory shRNAs of each of HAT1 or KAT8 in HepG2.2.5 cells. a Relative levels of HBsAg in HepG2.2.15 cells at 96 h after infection 
with lentiviral shRNAs of hit gene HAT1 and KAT8. The lentiviral vector served as a negative control. b Relative levels of HAT1 and KAT8 mRNA in 
HepG2.2.15 cells at 72 h after infection with shRNA lentivirus. Scrambled shRNA served as a negative control. (*P < 0.05, **P < 0.001). c Protein level 
of HAT1 and KAT8 in HepG2.2.15 cells after infection with most inhibitory lentiviral shRNAs. β-actin served as an internal control
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shRNA3 inhibited HBV replication by 0.51 (SD: 0.01) 
folds. HAT1 shRNA4 inhibited HBV replication by 0.37 
(SD: 0.04) folds. KAT8 shRNA1 inhibited HBV replication 
by 0.45 (SD: 0.02) folds. KAT8 shRNA2 inhibited HBV rep-
lication by 0.25 (SD: 0.05) folds. KAT8 shRNA3 promoted 
HBV replication by 0.02 (SD: 0.11) folds but this observa-
tion was not statistically significant (P > 0.05). Other than 
KAT8 shRNA3, all of the lentiviral shRNAs had a statisti-
cally significant inhibitory effect on HBV replication.
Furthermore, we also detected the inhibition effect of 
each shRNAs for both HAT1 and KAT8. It turned out 
that each four shRNAs for HAT1 effectively reduced 
HAT1 expression level (P  <  0.001 for all). For shRNA1 
and shRNA2 of KAT8, there was a significant knock-
down effect (P  <  0.01, respectively). KAT8 shRNA3 
restrained KAT8 replication by 0.29 (SD: 0.07) folds and 
this observation also had a statistically significant inhi-
bition (P < 0.05). The result above was shown that each 
shRNAs for KAT8 effectively reduced KAT8 levels. 
However, only 2 of them resulted in a lower of HBsAg 
whereas the third one had no effect. As a result, it might 
indicate that inhibition of KAT8 may not have an impact 
on HBsAg level.
After that, we tested the strongly inhibitory shRNA 
of each of HAT1 or KAT8 in HepG2.2.5 cells, HAT1 
shRNA1 and KAT8 shRNA1, respectively. There was 
strong evidence suggesting that both HAT1 shRNA1 
and KAT8 shRNA1 had a significant knockdown effect 
(P  <  0.001 and P  <  0.01, respectively), as observed via 
qRT-PCR and Western blot (Fig. 2b, c).
The levels of HBsAg, HBeAg, and HBV-DNA at 72 
and 96  h after shRNA transfection were determined. 
The expression of HBsAg was suppressed in these three 
samples at 72 or 96  h, compared to control follow-
ing HAT1 or KAT8 shRNA treatment (Fig.  3a). HBeAg 
was suppressed following KAT8 shRNA treatment only 
(Fig. 3b). As the duration of RNAi treatment progressed, 
the suppression of HBsAg or HBeAg expression was 
enhanced in all three samples after KAT8 shRNA treat-
ment (both P  <  0.0001). In contrast, up-regulation of 
HBsAg or HBeAg was observed between 72 and 96  h 
after HAT1 shRNA treatment (both P  <  0.0001). Fur-
thermore, HBV-DNA was also inhibited by HAT1 or 
KAT8 shRNAs treatment (Fig. 3c), but less inhibition of 
HBV-DNA was observed at 96  h, compared to at 72  h, 
after HAT1 or KAT8 shRNA treatment (both P < 0.0001). 
Moreover, the levels of HBsAg, HBeAg, and HBV-DNA 
were determined at 72 and 96  h after HAT1 inhibitor. 
The expression of HBsAg (Fig. 4a) and HBeAg (Fig. 4b) 
were suppressed by inhibitor 7476 (P  <  0.001) or 7641 
(P < 0.001) at both 72 and 96 h compared to control. No 
significant difference of HBV-DNA was observed fol-
lowing such treatments (Fig.  4c). There was significant 
suppression of HAT1 following inhibitor 7476 (P < 0.05) 
or 7641 (P < 0.0001) (Fig. 4d). It was demonstrated that 








































































Fig. 3 HAT1 and KAT8 regulate HBV replication by suppressing the 
expression of HBsAg, HBeAg and HBV-DNA. a Relative levels of HBsAg 
at 72 and 96 h after infection with lentiviral shRNAs. b Relative levels 
of HBeAg at 72 and 96 h after infection with lentiviral shRNAs. c Rela-
tive levels of HBV-DNA at 72 and 96 h after infection with lentiviral 
shRNAs. (*P < 0.05, **P < 0.001, ***P < 0.0001)
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similar but not exactly the same. The inhibitor potently 
reduced HBsAg throughout the 96  h trial but not the 
same as HAT1 shRNAs (Figs.  3a, 4a), and HBV-DNA 
was inhibited by HAT1 shRNAs treatment (Fig. 4b) but 
there was no significant difference of HBV-DNA follow-
ing inhibitor treatment (Fig. 3c).
HAT1 and KAT8 regulate the transcription level of HNF4A 
and PPARGC
To investigate the mechanism by which HAT1 or KAT8 
affected HBV replication, the expressions of HBV repli-
cation-related transcription factors Foxa1, Foxa2, Foxa3, 
CEBP, HNF1A, HNF1B, HNF4A, PPAR, FXR, FTF, and 
PPARGC were detected using qRT-PCR analysis.
The transcription levels of HNF4A were found to be 
suppressed by 0.44 (SD: 0.02) folds and 0.75 (0.04) folds 
in HepG2.2.15 cells infected with HAT1 shRNA and 
KAT8 shRNA, respectively (Fig. 5). The transcription lev-
els of PPARGC were found to be suppressed by 0.25 (SD: 
0.13) folds and 0.64 (SD: 0.02) folds in HepG2.2.15 cells 
infected with HAT1 shRNA and KAT8 shRNA, respec-
tively (Fig.  5). This suggests that the acetyltransferases 
(HAT1 or KAT8) might regulate HBV replication via the 
transcription factor HNF4A and PPARGC. Further, this 
suggests that HNF4A and PPARGC may also be impor-
tant in HBV regulation by HATs.
Discussion
HBV replication persists in chronic hepatitis B (CHB) 
patients, in whom there is an increased risk of developing 
heptocellular carcinoma (HCC) [13]. Current treatments 
for CHB include pegylated interferon alfa (PEG-IFNα) 
and nucleoside or nucleotide analogues (NUCs) [14, 
15]. However, PEG-IFNα therapy presents marked side 
effects [15] and ~40 % sustained virologic response [16]. 
Furthermore, NUCs drugs cannot completely clear HBV 
cccDNA from the hepatocyte and HBV mutants appear 
to be resistant to these drugs during therapy [17]. It is 
thus necessary to identify alternate targets for novel 
therapies to suppress HBV replication and to clear HBV 
[14, 18–20]. The formation of replicative intermediate 
cccDNA in the nucleus of infected hepatocytes, a process 
regulated by acetylated histones, is a key event in HBV 
replication [6, 8]. We thus hypothesize that HATs tightly 
regulate HBV replication and performed RNAi screening 
to proof this hypothesis.
The present study showed that HBV replication was 
regulated tightly by HAT1 and/or KAT8. However, the 
effects of HAT1 shRNAs and HAT1 inhibitors were not 
exactly the same, such different effects may be due to 
different inhibitions at mRNA/protein level by HAT1 
shRNAs and HAT1, which will be further clarified in 
future. Moreover, HBsAg, HBeAg and HBV-DNA were 
observed as being markedly reduced in HepG2.2.15 cells 
when HAT1 or KAT8 were knocked down. Interestingly, 
there was minimal up-regulation of HBV-DNA between 
72 and 96 h when HAT1 or KAT8 was knocked down. In 
contrast, there was down-regulation of HBsAg with time 
extension when KAT8 was knocked down. Indeed, there 
are inconsistent reports about the association between 
HBV-DNA and liver histology in the different statuses of 
HBeAg patients [21]. Moreover, a recent study revealed 
that large number of virions without HBV-DNA was 
existed [22], suggesting that HBsAg and/or HBeAg lev-
els probably do not reflect true HBV-DNA level but are 
instead reflective of the amount of HBV replication. From 
our qRT-PCR array, we identified a number of HBV-
replication-related regulators that were up-regulated by 
knockdown of each target gene, such as HNF1A [23] or 
HNF1B, as well as other transcription factors for HBV 
replication that were down-regulated, such as PPARGC. 
These HBV-replication-related factors [24, 25] may pref-
erentially regulate viral RNA synthesis, viral protein 
translation or viral DNA synthesis during virus lifecycle, 
thereby leading to different dynamics of HBsAg, HBeAg 
and HBV-DNA.
It has been demonstrated that HAT1 plays an impor-
tant role in controlling inflammatory NF-κB at the tran-
scriptional level by acetylation of the transcriptional 
regulator PLZF [26]. However, the differential regulation 
of HAT1 on HBV-replication-related transcription fac-
tors remains to be investigated. HNF4A has been demon-
strated to promote HBV replication via pgRNA in hepatic 
and non-hepatic cells [27]. HNF4A has been observed as 
being post-transcriptionally reduced by analogues based 
on the non-nucleoside natural product helioxanthin, sug-
gesting it as a potential therapeutic target in the manage-
ment of HBV [28]. In our study, we found that HAT1 or 
KAT8 all modulate HNF4A transcription. The peroxi-
some proliferator-activated receptors (PPARs), namely 
PPAR-α, PPAR-β, and PPAR-γ, are ligand-activated tran-
scription factors of the nuclear hormone receptor super-
family [24, 25]. These receptors act as lipid metabolism 
regulators and play key roles in cellular proliferation, dif-
ferentiation, and apoptosis [29, 30]. In this present study, 
PPARGC may be demonstrated to be another HBV tran-
scription modulator that is regulated by HAT1 and KAT8. 
PPARGC synergizes with HNF4A to activate downstream 
genes transcription and HBV replication [31]. These find-
ings suggest that HNF4A and PPARGC may be critical 
intermediate modulators that mediate regulation of HBV 
replication by histone acetyltransferases. In addition to 
this, HAT1 and KAT8 were also observed to differen-
tially modulate expression of HBV transcription regula-
tors, suggesting that they may regulate HBV in different 
manners.
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A more complete understanding of the underlying 
mechanisms involved in the interaction between HBV 
and its host factors will be valuable in the identification 
of new cellular drug targets. The potential use of the 
novel antiviral targets to inhibit viral replication via inter-
fering virus–host interaction, may have some advantages, 
such as fewer side effects compared to direct antiviral 
therapies. In addition, novel therapeutics with a broader 
spectrum of activity against the various HBV genotypes 
are necessary to overcome the vast genetic heterogeneity 
and antiviral drug resistance [32].
Conclusions
The present study showed that HAT1 and KAT8 (human 
acetyltransferases) play an important role in regulating 
HBV replication, indicating a potential underlying mech-
anism by which acetyltransferases influence HBV repli-
cation. Our observations may provide novel insights for 




The HBV-replication-stable HepG2.2.15 cell line was 
maintained in our laboratory, as previously described [9]. 
HEK293T cells were obtained from the American Type 
Culture Collection. HepG2.2.15 and HEK293T cells were 
maintained at 37  °C in DMEM medium, supplemented 
with 10 % fetal bovine serum (Life Technologies, Carls-











































































Fig. 4 The inhibition of each of HAT inhibitors on HBV replication or HAT1 expression. a Relative levels of HBsAg at 72 and 96 h after treatment 
of HAT inhibitors. b Relative levels of HBV-DNA at 72 and 96 h after treatment of HAT inhibitors. c Relative levels of HBeAg at 72 and 96 h after 
treatment of HAT inhibitors. d Relative levels of HAT1 mRNA in HepG2.2.15 cells at 72 h after treatment of HAT inhibitors. (*P < 0.05, **P < 0.001, 
***P < 0.0001)
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5 % CO2. G418 (Life Technologies, Carlsbad, CA, USA) 
was also added to the medium to a final concentration 
of 380 μg/mL to maintain the HepG2.2.15 cells [9]. The 
details of HAT1 inhibitors were given by the site: http://
www.selleck.cn/search.html?searchDTO.searchParam=
HAT+inhibitor&sp=HAT%252520inhibitor.
Preparation of shRNA library and screen
To identify which acetyltransferase genes are involved 
in HBV replication, RNAi screening was performed, 
as shown in Fig.  1a. RNAi screening has been widely 
used in the identification of host factors that regu-




































































































Fig. 5 Relative levels of HBV replication regulators at 72 h after lentiviral infection. Scrambled shRNA was used as a negative control (*P < 0.05, 
**P < 0.001, ***P < 0.0001)
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viruses, including hepatitis C virus (HCV) [33]. shR-
NAs against 15 human acetyltransferase genes were 
designed, using an online tool available from the 
Broad Institute’s RNAi Consortium (TRC) shRNA 
Library (http://www.broadinstitute.org/rnai/public/), 
a punchier lentiviral RNAi library that uses multi-
ple distinct shRNA to knockdown most of the known 
human and mouse genes [34]. Four pairs of oligos were 
synthesized for each gene and cloned into modified 
FuGw lentiviral vector, harboring the U6 promoter for 
shRNA expression and tandem dimer Tomato gene 
(Tdtomato) for infection indication. (All of the oligos 
and scramble shRNA sequences are listed in Addition-
alfile 1: Table  S1). All of the constructs were verified 
using colony PCR and using restriction enzyme diges-
tion and subsequent co-transfection with packaging 
plasmids (Life Technologies, Carlsbad, CA, USA) in 
HEK293T cells.
HepG2.2.15 cells were infected with pooled lentivi-
ral shRNA library in triplicate plates. The supernatant 
was collected 72 and 96 h after infection for Quantita-
tive Real-time PCR (qRT-PCR) and HBsAg detection, 
respectively. RNA was extracted from the cultured 
cells using Trizol (Life Technologies, Carlsbad, CA, 
USA) for qRT-PCR. The forward and reverse prim-
ers for pgRNA are listed in Additional file 2: Table S2. 
Cellular RNA was extracted using Trizol (Life Tech-
nologies, Carlsbad, CA, USA) and cDNA was prepared 
from 1  μg total RNA using the RevertAid™ Reverse 
Transcriptase kit (Thermo Fisher Scientific, Waltham, 
MA, USA). Amplification was performed as follows: 
94 °C for 2 min, then 40 cycles at 95 °C for 15 s, 60 °C 
for 30 s, 72 °C for 20 s, and 72 °C for 20 s. The primers 
for HAT1, KAT8 and other genes listed in Additional 
file 2: Table S2.
Western blot
The treated cells were lysated with RIPA buffer (Abcam, 
Cambridge, UK) and collected for western blot. Protein 
quantification was performed using BCA kit (Abcam, 
Cambridge, UK). Protein (10  μg) was loaded for elec-
trophoresis and transferred to PVDF membranes. The 
blots were blocked and labeled with primary antibodies 
(mouse anti-human HAT1, 1:2000 dilution; Santa Cruz 
Biotechnology, Dallas, TX, USA); rabbit anti-human 
KAT8, 1:2000 (Abcam, Cambridge, UK); or mouse anti-
human β-actin 1:5000 (Santa Cruz Biotechnology, Dallas, 
TX, USA) overnight. Membranes were incubated with 
the secondary antibody (goat anti-rabbit-HRP or goat 
anti-mouse-HRP, 1:5000 dilution each; Amersham Phar-
macia Biotech, Saclay, France). The signal was developed 
and imaged using ImageQuant™ LAS 4000 (Fujifilm, 
Tokyo, Japan).
Enzyme‑linked immunosorbent assay (ELISA)
To detect the HBV expression in HepG2.2.15 cells, 
HBsAg and HBeAg levels in the medium at 72 and 96 h 
after lentiviral shRNA infection were semi-quantitatively 
determined using enzyme-linked immunosorbent assay 
(ELISA) kits (Abbott Diagnostics, Lake Forest, IL, USA) 
per the manufacturer’s instructions. All experiments 
were performed in triplicate.
HBV DNA quantification
To detect the level of HBV replication in HepG2.2.15 
cells, supernatant HBV DNA levels in the medium at 72 
and 96 h after lentiviral shRNA infection were measured 
by the Applied Biosystems Real-Time PCR Prism 7500 
System (Applied Biosystems, Carlsbad, CA, USA). All 
experiments were performed in triplicate.
Cell proliferation assay
Cell proliferation assay was performed in triplicate, using 
CellTiter 96® AQueous One Solution Cell Proliferation 
Assay kit (Promega, Madison, WI, USA) at 96 h after len-
tiviral shRNA infection, per the manufacturer’s protocol.
Statistical analysis
The data are expressed as mean ± SD. One-way ANOVA 
and two-tailed Student’s t-tests were used for Figs.  2, 
3 and 4, using GraphPad Prism, Version 6.0 (GraphPad 
Software, San Diego, CA, USA). P-values <0.05 were con-
sidered statistically significant.
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